Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01714973
Other study ID # ST-02-12
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2012
Est. completion date October 2015

Study information

Verified date May 2019
Source Noveome Biotherapeutics, formerly Stemnion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and efficacy of ST266 in treating radiation burns of the skin in patients undergoing treatments for breast cancer and to compare ST266 treated burns with those treated with saline placebo controls.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- A signed IRB - approved Informed Consent;

- Women 18 - 80 years of age;

- Biopsy-proven diagnosis of breast cancer with the tumor surgically removed.

- Whole breast radiation with or without ipsilateral axilla radiation therapy recommended by her radiation oncologist.

- If a woman is of child-bearing potential, she and her partner must use an effective form of birth control.

- Willing to participate in the clinical study and comply with the requirements of the trial.

Exclusion Criteria:

- Abnormal liver or kidney function studies being greater than 2x the upper limit of normal.

- Patients on hemodialysis

- Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to patient compliance;

- History of non-compliance with treatment or clinical visit attendance.

- Participation in an investigational trial within 30 days of study entry.

- Women who are pregnant or lactating

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ST266
Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.

Locations

Country Name City State
United States Allegheny General Hospital Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Noveome Biotherapeutics, formerly Stemnion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Cosmesis Cosmesis will be evaluated by photography and investigator assessment using the cosmesis form in National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-39, A Randomized Phase III Study of Conventional Whole Breast Irradiation Versus Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer. The following factors will be evaluated in the skin: telangiectasia, atrophy, scarring, pigmentation, erythema, fat necrosis, and fibrosis. 6 and 12 months post-treatment
Primary Adverse Events (AEs) and Significant Adverse Events (SAEs) Start of therapy through six week follow-up visit
Secondary Skin inflammation start of therapy through six week follow-up visit
Secondary Quality of Life (QOL)scaled responses Quality of Life (QOL) will be evaluated using a QOL Assessment (general to breast cancer patients receiving radiation therapy following tumor removal) and a QOL Supplement (specific to subjects receiving trial treatment). Both documents include subsets of questions, each with a different subscale. The assessments include both lifestyle QOL factors (sleep, activity, friends/family, general life enjoyment, etc.) and breast condition (pain, appearance, ect.). This secondary endpoint will focus on the QOL Supplement, comparing breast condition by treatment, noting changes in both the medial and lateral aspects breast including breast texture (thickening and hardness), pain, tenderness, shape, sensitivity, swelling, redness, itching, flaking skin, blistering and fluid leak. The patient will note, for each item, in which side of the breast they are experiencing the negative breast condition or if there is no difference. start of therapy through one year follow-up
See also
  Status Clinical Trial Phase
Completed NCT02556632 - Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer Phase 2
Completed NCT02369835 - Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Phase 3
Recruiting NCT05284487 - Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel. N/A
Completed NCT03374995 - Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer N/A
Not yet recruiting NCT05114226 - A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury Phase 1
Withdrawn NCT05073172 - StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients N/A
Completed NCT01246973 - Oral Curcumin for Radiation Dermatitis Phase 2/Phase 3